Psilocybin Therapy for Depression in Bipolar II Disorder
(BAP Trial)

Recruiting in Palo Alto (17 mi)

Overseen byJoshua D Woolley, MD,PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of California, San Francisco

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing the safety and feasibility of using psilocybin, a substance from 'magic mushrooms,' to help people with Bipolar II Disorder who are currently depressed. Researchers want to see if this treatment can safely improve mood and quality of life for these patients. Psilocybin has shown promise as a treatment for depression and has been designated as a breakthrough therapy by the FDA.

Research Team

Joshua D Woolley, MD,PhD

Principal Investigator

University of California, San Francisco

David Guard, PhD

Principal Investigator

San Francisco State University

Eligibility Criteria

Inclusion Criteria

Age 30 to 65

Comfortable speaking and writing in English

Able to attend all in-person visits at UCSF as well as virtual visits

See 4 more

Treatment Details

Interventions

Psilocybin Therapy (Psychedelic)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Psilocybin therapyExperimental Treatment1 Intervention

Participants will receive one or two doses of psilocybin in a monitored setting approximately three weeks apart, with preparation sessions before and integration sessions after.